Precision medicine
meets infection
Inthelia is developing an innovative biomarker-guided, host-targeted therapy to treat serious infection & other pathogen-induced barrier dysfunctions.
Inthelia is a cutting-edge biopharmaceutical company focused on transforming the landscape of precision medicine in infection. Our goal is to make a significant difference in treating infectious disease and aim to positively impact the health of millions of people across the world.
Committed to harnessing the power of personalized approaches, we leverage advanced technologies and deep molecular insights to develop host targeted therapies tailored to individual patients suffering from bacterial, fungal or viral infections.
Using a host targeted approach we aim to redefine infectious disease treatment by offering solutions that not only enhance efficacy but also minimize side effects and improve patient outcomes from an early stage in disease progression.
1 in 5 deaths
in the world is attributed to sepsis
49 millions cases
of sepsis annually compared to 18 million cases of cancer annually
No drugs approved
to treat the underlying causes of sepsis
11 millions deaths
worldwide - compared to 9 millions deaths from cancer
Leading cause of death
in children under 5 years old
Treatment relies solely
on anti microbials (most antibiotics)
1 in 5 deaths
in the world is attributed to sepsis
49 millions cases
of sepsis annually compared to 18 million cases of cancer annually
No drugs approved
to treat the underlying causes of sepsis
11 millions deaths
worldwide - compared to 9 millions deaths from cancer
Leading cause of death
in children under 5 years old
Treatment relies solely
on anti microbials (most antibiotics)
To harness the power of cutting-edge science and innovative technologies to develop and deliver transformative precision therapies to treat infectious disease.
Investors
Inthelia believes that the solution is not more anti-microbials but a complete paradigm shift towards a new type of drug therapy that works along side existing treatments.
Investing in host-targeted therapy presents a promising opportunity in the healthcare sector. As the understanding of host-pathogen interactions deepens, there’s growing recognition of the potential benefits of therapies that focus on modulating host factors.
